SCHEMBL10322196

SCHEMBL10322196

Nc1cc(C(=O)NCc2cccs2)ccc1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.60
ALDH1A1 P00352 3/20 0.60
RAB9A P51151 3/20 0.60
LMNA P02545 3/20 0.60
NPC1 O15118 1/20 0.60
HPGD P15428 6/20 0.59
SMN1; SMN2 Q16637 2/20 0.58
USP2 O75604 1/20 0.55
HTT P42858 1/20 0.55
THRB P10828 1/20 0.54
TSHR P16473 1/20 0.53
POLB P06746 2/20 0.53
MAPK14 Q16539 1/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
ALOX15 P16050 1/20 0.52
MAPK1 P28482 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MEN1 O00255 1/20 0.51
PKM P14618 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2319467 0.88 HPGD (0.64) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL10322195 0.85 KDM4E (0.58) KDM4EALDH1A1RAB9ALMNANPC1
SCHEMBL10321762 0.84 HPGD (0.62) KDM4EALDH1A1RAB9AHPGDSMN1; SMN2
SCHEMBL2400629 0.80 HPGD (0.74) KDM4EALDH1A1RAB9ALMNANPC1
SCHEMBL5551614 0.80 HPGD (0.74) ALDH1A1RAB9AHPGDSMN1; SMN2USP2
SCHEMBL10630917 0.80 LMNA (0.75) KDM4ERAB9ALMNANPC1HPGD
SCHEMBL31396768 0.80 HPGD (0.68) KDM4EALDH1A1RAB9ALMNAHPGD
SCHEMBL5334839 0.79 HPGD (0.68) KDM4EALDH1A1RAB9ALMNANPC1
SCHEMBL10318404 0.78 PPARG (0.64) KDM4EALDH1A1RAB9ALMNANPC1
SCHEMBL10321815 0.77 SMN1; SMN2 (0.63) KDM4EALDH1A1RAB9ALMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012098065-A1 PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 WO claimed
US-20120184542-A1 PYRIDO PYRIMIDINES ANDERSON KEVIN (US) 2012-07-19 US claimed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 US claimed
WO-2012098065-A1 PYRIDO PYRIMIDINES FOR USE AS DYRK1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2012-07-26 WO disclosed
US-20120184542-A1 PYRIDO PYRIMIDINES ANDERSON KEVIN (US) 2012-07-19 US disclosed
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES LUK KIN-CHUN (US) 2012-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184542-A1 PYRIDO PYRIMIDINES TYMS, TYMP, DPYD KDM4E 2024/4885ALDH1A1 2619/4885RAB9A 2086/4885
US-20120184562-A1 1,6- AND 1,8-NAPHTHYRIDINES PSEN1, BRCA1, PSEN2 KDM4E 2930/4885ALDH1A1 738/4885RAB9A 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.